Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?
Does the ENE of 1 mm or less versus >1 mm as in ECOG 3311 affect your decision?
Answer from: Radiation Oncologist at Academic Institution
I'm wary of de-escalating treatment without phase 3 data supporting that decision. So any ECE, I treat with 66 Gy and concurrent chemo.
Sign In
or
Register
to read more
19938
Related Questions
What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?
Is there a scenario in which you would consider observation for T4a SCC involving the mandible?
What is the preferred neoadjuvant/adjuvant chemotherapy regimen for HPV-associated nasopharyngeal cancer?
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
How do you approach postoperative radiation therapy in a patient with head and neck cancer who has high risk of recurrence in the setting of active epidermolysis bullosa?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
For a patient with a salivary gland tumor with evidence of local recurrence would you recommend 6 weekly fractions if giving RT alone?
How would you approach a patient with a carotid body tumor and metastasis to the cervical lymph node?
How are you integrating the findings from KEYNOTE-689 into daily practice?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?